The Champalimaud Foundation (CF) was established in 2005 as a worldwide reference for scientific research and clinical practice. Located in a beautiful setting by the Tagus river in the city of Lisbon, Portugal, the Champalimaud Centre for the Unknown (CCU) is a vibrant scientific and clinical institution where hundreds of national and international (+40 EU and non-EU nationalities) scientists, support staff, physicians, and other healthcare professionals work together to investigate fundamental biological processes and search for effective solutions to alleviate the burden of oncological and neurological diseases, while providing state-of-the-art care to patients.

The Max-Planck-Institute for Biology of Ageing (MPI-AGE) aims to unravel the molecular, physiological and evolutionary mechanisms underlying the ageing process. As we age, many of our body functions decline, often accompanied by the development of complex and chronic diseases such as type 2 diabetes, cancer, cardiovascular, and neurodegenerative diseases. Our mission is to understand how we can intervene to mitigate or even prevent these age-related diseases and pave the way for a healthier ageing. Currently, much of the research at the institute focuses on three topics: the molecular genetics of ageing, the study of the ageing brain, and the role of mitochondria in ageing processes. In addition, research groups are investigating how DNA repair and nutrient sensing influence ageing.

Over 50% of the cork produced worldwide comes from Portugal. This material, used for products that range from wine stoppers to the isolation of spaceships, is at the heart of two ERC research grants developed at ITQB NOVA over the last years. The reason is that half of cork’s weight is made up of suberin, a plant polymer with remarkable antimicrobial, anti-biofouling and hydrophobic properties. Suberin can mimic natural processes and offer sustainable alternatives for combating fungal infections, as explored in the project MIMESIS – “Development of biomaterials through mimesis of plant defensive interfaces to fight wound infections”, but also for encapsulation technologies in the food and drug industries, as investigated in SNAIL – “High-performance hydrophobic suberin nanoparticles for the generation of liquid-air biphasic droplets with application in food and therapeutics”. Both projects were led by ERC Grantee Cristina Silva Pereira, head of the Applied and Environmental Mycology lab of ITQB NOVA.

ITQB NOVA is a scientific research and advanced training institute of NOVA University Lisbon. The institute is located in Oeiras, a seaside town with the highest GDP/capita and the most educated population in the country. The institution excels in Molecular Biosciences across diverse disciplines, contributing to societal challenges focused on the well-being of human societies and on the environment.

The Institute of Biotechnology and Biomedicine (IBB) was created 52 years ago and was the pioneer of Spanish research institutes within a University. The IBB is located on the campus of the Autonomous University of Barcelona (UAB) and was previously known as the Institute of Fundamental Biology. In 2000, the Institute’s approach evolved towards a multidisciplinary and cooperative research in the area of biotechnological applications in biomedicine and consequently the name was changed. In addition, the strategic objectives of the entire unit were also reformulated, in favour of potentiating translational projects aimed at understanding the molecular bases of diseases and generating instruments, mainly drugs and vaccines, to fight them.

ISGlobal addresses key global health challenges related to infectious diseases, chronic non-communicable diseases, and environmental factors, including climate. We aim to go beyond state-of-the-art by strengthening research within and across our 5 research programmes and promoting innovation and collaboration on methodological issues through cross-faculty knowledge hubs.

The Global Viral and Bacterial Infections Programme aims to reduce the relevant viral and bacterial disease burden by generating knowledge that translates into novel tools and strategies for their prevention, diagnosis, and treatment. It has a multidisciplinary and translational research portfolio ranging from basic science to clinical, epidemiological, and public health-oriented research. It works at various steps of the prevention-treatment cascade for pathogens such as M. tuberculosis, non-tuberculous Mycobacteria, antimicrobial resistant bacteria, other bacteria of public health relevance (pneumococcus, group B streptococcus, etc.), CMV, HIV, arboviruses, and viral hepatitis.

The profound impact of infectious diseases on society, notably underscored during the COVID-19 pandemic, accentuates the imperative for in-depth research to comprehend the intricate dynamics of infectious agents. This includes understanding their modes of transmission, the factors within hosts that influence disease outcomes, and the identification of effective intervention strategies. The urgency of this research has been particularly evident during the pandemic, highlighting the pivotal role of scientific investigation in addressing global health challenges.

The Infectious Diseases Research Program at CIC bioGUNE stands as a vanguard in scientific exploration, pioneering an initiative committed to unraveling the complex and dynamic molecular foundations of infectious diseases. 

Cancer, a complex group of diseases characterized by uncontrolled cell growth, poses a formidable challenge worldwide. Its impact on society is profound, affecting millions of lives and presenting a substantial burden on healthcare systems. The need for comprehensive research to unravel the intricacies of cancer biology and develop advanced strategies for diagnosis and treatment has never been more crucial.

The Cancer Research Program at CIC bioGUNE is a multidimensional exploration focused on unraveling the complexities of cancer, specifically targeting Prostate, Breast, Colorectal, and Liver cancers. 

Rare diseases, often referred to as orphan diseases, encompass a broad spectrum of disorders that collectively affect a relatively small number of individuals within a population. These diseases are characterized by their low prevalence, typically afflicting fewer than 1 in 2,000 people. Despite their individual rarity, the cumulative impact of rare diseases is substantial, with estimates suggesting that there are thousands of distinct rare diseases, collectively affecting millions of people worldwide.

Many rare diseases are chronic, debilitating, and life-threatening, often manifesting early in life. Due to their complex and often unpredictable nature, these diseases can lead to significant physical, emotional, and financial burdens on patients and their caregivers. Moreover, the lack of effective treatments exacerbates the challenges faced by individuals living with rare diseases.

Harnessing knowledge of plant biology for crop improvement, infectious diseases; RNA/nucleic acids in health and disease; correlative approaches to connect dynamics and structure of living systems; cancer biology; and brain disorders.